Poseida Therapeutics is developing next-generation gene engineering technologies. Using their proprietary genetic engineering platform combining the piggyBac DNA Modification System, Cas-CLOVER Gene Editing System and Nanparticle/AAV Delivery Technology, Poseida is developing single treatment cures that efficiently deliver genetic cargo into cells. Poseida’s gene engineering technologies represent the next wave of innovation and brings hope to patients with cancer and genetic disease. Poseida is advancing product candidates including CAR-T therapies to harness the power of a patient’s own immune system.

<p>Poseida Therapeutics is developing next-generation gene engineering technologies. Using their proprietary genetic engineering platform combining the piggyBac DNA Modification System, Cas-CLOVER Gene Editing System and Nanparticle/AAV Delivery Technology, Poseida is developing single treatment cures that efficiently deliver genetic cargo into cells.</p>
<p>Poseida’s gene engineering technologies represent the next wave of innovation and brings hope to patients with cancer and genetic disease. Poseida is advancing product candidates including CAR-T therapies to harness the power of a patient’s own immune system.</p>


Poseida Therapeutics

Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? - Yahoo Finance

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma - PR Newswire

 More news from Dow Jones Newswires 

Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance

 NTT DATA's Acquisition of Niveus Solutions to Strengthen Google Cloud Capabilities 

Why Poseida Therapeutics Stock Is Rising 228% - Barron's

Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show - Endpoints News

 Roche commences tender offer for all shares of Poseida Therapeutics (PSTX) 

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma - PR Newswire

 Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash 

 Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion -- Update 

Roche inks $1.5B Poseida buyout to land off-the-shelf CAR ...

#CellandGeneTherapies are transforming our approach to treating disease, offering more precise disease-modifying and, in some cases, potentially curative solutions that give new hope to patients. This potential was evident when I attended #CGMesa24 recently, where scientific progress in the field took the spotlight and stories highlighting the impact on patients served as a powerful reminder of why our efforts matter and the power innovation holds to change lives.
 
I was delighted to join a fireside chat with Kristin Yarema, Ph.D., President and CEO of Poseida Therapeutics – one of our key innovation partners in cell therapy – to discuss the advances Astellas is making in cell and gene therapy. 
 
In addition, my colleagues Richard Wilson, Primary Focus Lead, Genetic Regulation, and Ha Tran, MD, MS, Head of Medical Development, Cell and Gene Therapy, shared their expertise during the meeting, addressing critical challenges and opportunities in the field alongside updates on our work in cell and gene therapy. 
 
A few key insights from the event that resonated with me: 
New approvals are rapidly advancing. We’ve seen a number of high profile approvals in areas such as advanced synovial sarcoma and Hemophilia B, and up to 14 cell and gene therapy approvals are expected this year across the US and EU – signaling positive momentum toward the FDA’s goal of 10 to 20 approvals per year starting in 2025.
After seeing somewhat of a slowdown in 2022 and 2023, investment in cell and gene therapy is resurging. Strong clinical data and positive real-world evidence are supporting investor confidence, particularly in late-stage assets, setting the stage for further innovation and growth.
Manufacturing remains a significant challenge to ensuring these innovative therapies reach patients in need. Manufacturing methods vary depending on the type of therapy and cell source, with differing levels of complexity. Navigating this complexity requires substantial and early investment to standardize protocols and build the infrastructure needed to enable scaling up. 
 
Taken together, these insights highlight the significant progress we’re making, but they also underscore the work ahead. I’m proud to be leading a team at Astellas Pharma who shares this commitment to bringing transformative therapies to patients in need. 
 
#ScienceFirstForPatients #ChangingTomorrow 

We’re excited to highlight our interim Phase 1 data from lead #allogeneic #CART program, P-BCMA-ALLO1, targeting multiple myeloma, alongside preclinical updates on P-CD19CD20-ALLO1 for B-cell malignancies. Don’t miss all the details at #ASH24!

https://lnkd.in/e-S-tFeJ

#CapacitytoCure #celltherapy

 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, PSTX, AE, PFIE on Behalf of Shareholders 

Roche Launches $9/Share Cash Tender Offer for Poseida Therapeutics, CVR Could Add $4 More - StockTitan

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - PR Newswire

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 - PR Newswire

Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - PR Newswire

Roche makes takeover bid for Poseida Therapeutics Inc - European Biotechnology News


              Pioneering Advances in Cell Therapy: Kristin Yarema, President & CEO of Poseida Therapeutics — Biotech2050 Podcast
            

Reflecting on the past year, we are grateful for the numerous achievements and milestones we've reached together. We wish all a happy and healthy New Year. Here's to a bright future ahead!

Honoring the brave men and women who have served in the military today and every day. Your courage, sacrifice, and commitment to our nation inspires us all. Thank you for your service.

#PoseidaProud #HonoringHeroes #CapacitytoCure 

Roche to acquire Poseida Therapeutics for $1.5bn - Yahoo Finance


                        
                            
                                Coming Soon: An Off-the-Shelf CAR T Therapy for Myeloma
                                
                                    
                                                                                    AJMC
                                                                             | 
                                    October 2, 2024
                                
                            
                        
                    

Roche Acquires Poseida for $1.5B - San Diego Business Journal

“showing promise in multiple myeloma”

Roche in $1.5 bn deal to buy Poseida Therapeutics - Medical Xpress

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline - PR Newswire

Roche said it didn't want to buy Poseida last year: A look at how the $1.5B buyout came to be - Fierce Biotech

Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet - Yahoo Finance

 Roche Acquires Poseida for $1.5B 

We are so proud to be recognized as a BioSpace Best Place to Work for the second year in a row! A big thanks to our dedicated, passionate, and patient-centric team for all their hard work and earning this recognition.

More on what makes us a #bestplacetowork: https://lnkd.in/e5AC_YG7

#CapacitytoCure #PoseidaProud

Roche Agrees to Acquire Poseida Therapeutics - Contract Pharma

Roche Buys Poseida for up to $1.5B, Leaning Into Off-the-Shelf CAR T - BioSpace

Our CEO, Kristin Yarema, Ph.D., will be providing a corporate presentation at Stifel’s 2024 Healthcare Conference on Monday, November 18.

The presentation will be webcast live on our website at https://lnkd.in/euY5mmFc, with a replay available shortly thereafter.

 #CapacitytoCure #celltherapy #geneticmedicines

Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald - Yahoo Finance

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™

 Roche Acquires Poseida Therapeutics for $1.5 Billion 

Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies - Roche

Poseida Therapeutics guns again for IPO

 Kuehn Law Encourages PSTX, BERY, PLL, and RKDA Investors to Contact Law Firm 

 European stocks echo global market downturn on tariff risk; auto shares slump 

 Roche: launch of takeover bid for Poseida Therapeutics 

 $TOCKHOLDER ALERT: The M&A Class Action Firm Urges Shareholders of PFIE, PSTX, ARCH, B to Take Action 

UPDATE: After FDA's CAR-T concerns, Poseida's Roche ...

Poseida Therapeutics (PSTX) to Present at Major Stifel, Piper Sandler Healthcare Conferences - StockTitan

PSTX - Poseida Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients - PR Newswire

Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Awaiting IPO, Poseida Therapeutics nips in a quick $110M ...

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - BioSpace

POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX - Business Wire

Roche to Acquire Poseida Therapeutics in $1.5B Cell Therapy Deal - StockTitan

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Purchased by Barclays PLC - MarketBeat

 Roche buys out CAR-T partner Poseida for $1B upfront 

 Poseida downgraded to Market Perform from Outperform at William Blair 

Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance

PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus - PR Newswire

Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma - CGTLive™


                        
                            
                                Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
                                
                                    
                                        
                                        Press Release
                                     | 
                                    December 9, 2024
                                
                            
                        
                    

 Roche to buy cell therapy developer Poseida for $1B 

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. - PR Newswire

 Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies 

Roche inks $1.5B Poseida buyout, betting off-the-shelf CAR-Ts will democratize access to cell therapies - Fierce Biotech

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - PR Newswire

                                    Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells
                                

Poseida Therapeutics to Present at Two Upcoming Investor Conferences - PR Newswire

 Poseida Therapeutics, Inc. Highlights Positive Interim Phase 1 Results for P-Bcma-Allo1 and Preclinical Data for Dual Car-T P-Cd19cd20-Allo1 At the 66Th American Society of Hematology Annual Meeting 


                        
                            
                                Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
                                
                                    
                                        
                                        Press Release
                                     | 
                                    November 14, 2024
                                
                            
                        
                    

 Auto stocks lead losses in Europe on Trump’s tariff risk 

Poseida is going live at 10 am ET. Join our exciting #celltherapy R&D Day, where we’ll share the latest on our clinical and early-stage cell therapy programs targeting #oncology and #autoimmune disease: https://lnkd.in/e9a5C_eJ 
 
More details in today’s news: https://lnkd.in/esP6E_Uh
 
#CapacitytoCure #allogeneic #CART

Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B - Yahoo Finance

Poseida Therapeutics (NASDAQ:PSTX) Sees Strong Trading Volume - What's Next? - MarketBeat


                        
                            
                                Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
                                
                                    
                                        
                                        Press Release
                                     | 
                                    November 26, 2024
                                
                            
                        
                    

Poseida Therapeutics executive chairman sells $283,866 in stock - Investing.com

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis - Yahoo Finance

 $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of B, PSTX, and ZUO 

Roche to acquire cell therapy maker Poseida Therapeutics in $1.5 bln deal - Reuters

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer - PR Newswire

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion - The Wall Street Journal

 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, ZUO, MNTX on Behalf of Shareholders 

Join us at our November A2I Coffee Club on November 21 from 6:30pm-7:30pm on Zoom! This time we will focus on the Science and Scope of CAR T-cell Therapy with two specialists from Poseida Therapeutics! Register at https://lnkd.in/gnyfbSpU or by scanning QR code on flyer. Visit AWIS.org for membership details and email A2i@AWISSD.org for more meeting info.

 Cantor Fitzgerald Downgrades Poseida Therapeutics, Inc (PSTX) to Neutral 

 Auto stocks lead losses in Europe on Trump's tariff risk 

 SDBJ Insider 

Roche acquires CAR-T developer Poseida Therapeutics for $1.5 billion - BioPharma-Reporter.com

PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors - Barron's

 Roche: completes acquisition of Poseida Therapeutics 

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 - PR Newswire


                        
                            
                                CAR-T and Related Therapies Home In on Autoimmune Disease
                                
                                    
                                                                                    BioSpace
                                                                             | 
                                    November 4, 2024
                                
                            
                        
                    

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology - PR Newswire

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

 Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting 


                        
                            
                                Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
                                
                                    
                                                                                    CGTLive
                                                                             | 
                                    November 17, 2024
                                
                            
                        
                    


                        
                            
                                Pioneering Advances in Cell Therapy: Kristin Yarema, President & CEO of Poseida Therapeutics
                                
                                    
                                                                                    Biotech 2050
                                                                             | 
                                    November 20, 2024
                                
                            
                        
                    

Poseida Therapeutics

Business:

Drug notes:

About: